Latest Sense Stories
CARLSBAD, Calif., June 11 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Jefferies 3rd Annual Healthcare Conference on Wednesday, June 17, 2009, at 8:00 a.m. ET in New York. A live audio webcast of the presentation will be available on the "Investor Center" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available...
CARLSBAD, Calif., June 5 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 8th Annual Needham Life Sciences Conference on Thursday, June 11, 2009, at 1:00 p.m. ET at the New York Palace Hotel. A live audio webcast of the presentation will be available on the "Investor Center" section of the Company's Web site, www.isispharm.com. A replay of the presentation...
CARLSBAD, Calif., June 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Goldman Sachs 30th Annual Global Healthcare Conference on Wednesday, June 10, 2009, at 4:30 p.m. ET at the Grand Hyatt Hotel in New York City. A live audio webcast of the presentation will be available on the "Investor Center" section of the Company's Web site, www.isispharm.com. A...
The relationship between the dental disease periodontitis and coronary heart disease (CHD) has been known for several years. Although a genetic link seemed likely, until now its existence was uncertain. Now, for the first time, scientists have discovered a genetic relationship between the two conditions, a researcher told the annual conference of the European Society of Human Genetics today (Monday 25 May).Dr. Arne Schaefer, of the Institute for Clinical Molecular Biology, University of Kiel,...
Research provides evidence that different types of painful stimuli are detected by different subsets of pain-sensing neurons in skinYou can tell without looking whether you've been stuck by a pin or burnt by a match. But how? In research that overturns conventional wisdom, a team of scientists from the California Institute of Technology (Caltech) and the University of California, San Francisco (UCSF), have shown that this sensory discrimination begins in the skin at the very earliest stages...
WASHINGTON and CARLSBAD, Calif., May 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Isis and collaborators presented data on numerous advanced programs from Isis' cardiovascular franchise. The data were presented during the Arteriosclerosis, Thrombosis and Vascular Biology's (ATVB) Annual Conference. The presentations included data from a post-hoc analysis of a recently completed clinical study of mipomersen in which treatment with mipomersen...
DENVER and CARLSBAD, Calif., April 20 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Isis and its collaborators presented results on antisense inhibition of novel targets that could offer new mechanisms to treat cancer during the American Association for Cancer Research (AACR) meeting. Research conducted by Isis and its collaborators demonstrated the feasibility of targeting a large non-coding RNA, sigma RNA also known as Malat-1, that could offer...
Motion illusions reveal new insights into perceptionIn the classic waterfall illusion, if you stare at the downward motion of a waterfall for some period of time, stationary objects "” like rocks "” appear to drift upward. MIT neuroscientists have found that this phenomenon, called motion aftereffect, occurs not only in our visual perception but also in our tactile perception, and that these senses actually influence one another. Put another way, how you feel the world can actually change...
CARLSBAD, Calif., April 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Lloyd G. Tillman, Ph.D., Executive Director of Pharmaceutical Development of Isis has been awarded the American Pharmacists Association's (APhA) 2009 Ebert Prize. Dr. Tillman received the award at the APhA Annual Meeting and Exposition, April 3-6, 2009, in San Antonio, TX, for work published in the Journal of Pharmaceutical Sciences entitled "Oral Delivery of Antisense...
COPENHAGEN, March 20 /PRNewswire/ -- Santaris Pharma announced today that the fourth LNA-based drug has been brought into the clinic. In the USA several patients with cancer have now been treated with the Company's Survivin inhibitor, which is jointly developed by Santaris Pharma and Enzon Pharmaceuticals. The U.S. Food and Drug Administration (FDA) recently accepted Enzon PharmaÂÂceutical's Investigational New Drug (IND) application for the use of the LNA-based Survivin...
